Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Implementation and effectiveness of evriMED with short messages service (SMS) reminders and tailored feedback compared to standard care on adherence to treatment among tuberculosis patients in Kilimanjaro, Tanzania: proposal for a cluster randomized controlled trial.

Sumari-de Boer M, Pima FM, Ngowi KM, Chelangwa GM, Mtesha BA, Minja LM, Semvua HH, Mpagama S, Mmbaga BT, Nieuwkerk PT, Aarnoutse RE.

Trials. 2019 Jul 12;20(1):426. doi: 10.1186/s13063-019-3483-4.

2.
3.
4.

Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.

Juma SP, Maro A, Pholwat S, Mpagama SG, Gratz J, Liyoyo A, Houpt ER, Kibiki GS, Mmbaga BT, Heysell SK.

BMC Infect Dis. 2019 Feb 7;19(1):129. doi: 10.1186/s12879-019-3757-1.

5.

Evaluation of cytokines in peripheral blood mononuclear cell supernatants for the diagnosis of tuberculosis.

Sariko M, Maro A, Gratz J, Houpt E, Kisonga R, Mpagama S, Heysell S, Mmbaga BT, Thomas TA.

J Inflamm Res. 2018 Dec 24;12:15-22. doi: 10.2147/JIR.S183821. eCollection 2019.

6.

Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults.

Mbelele PM, Mohamed SY, Sauli E, Mpolya EA, Mfinanga SG, Addo KK, Heysell SK, Mpagama SG.

Int J Mycobacteriol. 2018 Oct-Dec;7(4):299-309. doi: 10.4103/ijmy.ijmy_135_18.

7.

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi: 10.1093/cid/ciy611.

PMID:
30496461
8.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

PMID:
30496460
9.

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T, Lee PS, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S317-S326. doi: 10.1093/cid/ciy609.

PMID:
30496457
10.

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec.

11.

Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy.

Ahmed MIM, Ntinginya NE, Kibiki G, Mtafya BA, Semvua H, Mpagama S, Mtabho C, Saathoff E, Held K, Loose R, Kroidl I, Chachage M, von Both U, Haule A, Mekota AM, Boeree MJ, Gillespie SH, Hoelscher M, Heinrich N, Geldmacher C.

Front Immunol. 2018 Sep 28;9:2247. doi: 10.3389/fimmu.2018.02247. eCollection 2018.

12.

Therapeutic Drug Monitoring: The Need for Practical Guidance.

Alffenaar JC, Heysell SK, Mpagama SG.

Clin Infect Dis. 2019 Mar 5;68(6):1065-1066. doi: 10.1093/cid/ciy787. No abstract available.

PMID:
30219826
13.

Platelet-monocyte interaction in Mycobacterium tuberculosis infection.

Kullaya V, van der Ven A, Mpagama S, Mmbaga BT, de Groot P, Kibiki G, de Mast Q.

Tuberculosis (Edinb). 2018 Jul;111:86-93. doi: 10.1016/j.tube.2018.05.002. Epub 2018 May 8.

14.
15.

Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment.

Zentner I, Modongo C, Zetola NM, Pasipanodya JG, Srivastava S, Heysell SK, Mpagama S, Schlect HP, Gumbo T, Bisson GP, Vinnard C.

Int J Infect Dis. 2018 Mar;68:18-23. doi: 10.1016/j.ijid.2017.12.017. Epub 2017 Dec 15.

16.

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ; PanACEA Consortium.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01054-17. doi: 10.1128/AAC.01054-17. Print 2017 Nov.

17.

Correction: Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis.

Operario DJ, Koeppel AF, Turner SD, Bao Y, Pholwat S, Banu S, Foongladda S, Mpagama S, Gratz J, Ogarkov O, Zhadova S, Heysell SK, Houpt ER.

PLoS One. 2017 Jul 7;12(7):e0181284. doi: 10.1371/journal.pone.0181284. eCollection 2017.

18.

Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis.

Operario DJ, Koeppel AF, Turner SD, Bao Y, Pholwat S, Banu S, Foongladda S, Mpagama S, Gratz J, Ogarkov O, Zhadova S, Heysell SK, Houpt ER.

PLoS One. 2017 May 18;12(5):e0176522. doi: 10.1371/journal.pone.0176522. eCollection 2017. Erratum in: PLoS One. 2017 Jul 7;12 (7):e0181284.

19.

Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6.

Ruhwald M, de Thurah L, Kuchaka D, Zaher MR, Salman AM, Abdel-Ghaffar AR, Shoukry FA, Michelsen SW, Soborg B, Blauenfeldt T, Mpagama S, Hoff ST, Agger EM, Rosenkrands I, Aagard C, Kibiki G, El-Sheikh N, Andersen P.

Sci Rep. 2017 Apr 7;7:45969. doi: 10.1038/srep45969.

20.

Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania.

Ebers A, Stroup S, Mpagama S, Kisonga R, Lekule I, Liu J, Heysell S.

PLoS One. 2017 Jan 31;12(1):e0170663. doi: 10.1371/journal.pone.0170663. eCollection 2017.

21.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.

Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.

22.

Evaluation of the Antibody in Lymphocyte Supernatant Assay to Detect Active Tuberculosis.

Sariko M, Anderson C, Mujaga BS, Gratz J, Mpagama SG, Heysell S, Kibiki G, Mmbaga B, Houpt E, Thomas T.

PLoS One. 2017 Jan 13;12(1):e0169118. doi: 10.1371/journal.pone.0169118. eCollection 2017.

23.

Glycated hemoglobin screening identifies patients admitted for retreatment of tuberculosis at risk for diabetes in Tanzania.

Sariko ML, Mpagama SG, Gratz J, Kisonga R, Saidi Q, Kibiki GS, Heysell SK.

J Infect Dev Ctries. 2016 Apr 28;10(4):423-6. doi: 10.3855/jidc.7324.

24.

Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs.

Heysell SK, Pholwat S, Mpagama SG, Pazia SJ, Kumburu H, Ndusilo N, Gratz J, Houpt ER, Kibiki GS.

Antimicrob Agents Chemother. 2015 Nov;59(11):7104-8. doi: 10.1128/AAC.01117-15. Epub 2015 Aug 24.

25.

The Influence of Mining and Human Immunodeficiency Virus Infection Among Patients Admitted for Retreatment of Tuberculosis in Northern Tanzania.

Mpagama SG, Lekule IA, Mbuya AW, Kisonga RM, Heysell SK.

Am J Trop Med Hyg. 2015 Aug;93(2):212-5. doi: 10.4269/ajtmh.15-0189. Epub 2015 May 26.

26.

Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.

Ndusilo ND, Heysell SK, Mpagama SG, Gratz J, Segesela FH, Pazia SJ, Wang XQ, Houpt ER, Kibiki GS.

PLoS One. 2015 Mar 27;10(3):e0122769. doi: 10.1371/journal.pone.0122769. eCollection 2015.

27.

Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.

Mpagama SG, Ndusilo N, Stroup S, Kumburu H, Peloquin CA, Gratz J, Houpt ER, Kibiki GS, Heysell SK.

Antimicrob Agents Chemother. 2014;58(2):782-8. doi: 10.1128/AAC.01549-13. Epub 2013 Nov 18.

28.

Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.

Mpagama SG, Houpt ER, Stroup S, Kumburu H, Gratz J, Kibiki GS, Heysell SK.

BMC Infect Dis. 2013 Sep 14;13:432. doi: 10.1186/1471-2334-13-432.

29.

Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.

Mpagama SG, Heysell SK, Ndusilo ND, Kumburu HH, Lekule IA, Kisonga RM, Gratz J, Boeree MJ, Houpt ER, Kibiki GS.

PLoS One. 2013 May 13;8(5):e62034. doi: 10.1371/journal.pone.0062034. Print 2013.

30.

Comparison of overnight pooled and standard sputum collection method for patients with suspected pulmonary tuberculosis in northern Tanzania.

Mpagama SG, Mtabho C, Mwaigwisya S, Mleoh LJ, Boer IM, Heysell SK, Houpt ER, Kibiki GS.

Tuberc Res Treat. 2012;2012:128057. doi: 10.1155/2012/128057. Epub 2012 Jan 19.

31.

Plasma drug activity assay for treatment optimization in tuberculosis patients.

Heysell SK, Mtabho C, Mpagama S, Mwaigwisya S, Pholwat S, Ndusilo N, Gratz J, Aarnoutse RE, Kibiki GS, Houpt ER.

Antimicrob Agents Chemother. 2011 Dec;55(12):5819-25. doi: 10.1128/AAC.05561-11. Epub 2011 Oct 3.

Supplemental Content

Loading ...
Support Center